STOCK TITAN
  1. Home
  2. News
  3. RDHL

Redhill Biopharm - RDHL STOCK NEWS

Welcome to our dedicated page for Redhill Biopharm news (Ticker: RDHL), a resource for investors and traders seeking the latest updates and insights on Redhill Biopharm stock.

Company Overview

RedHill Biopharma Ltd (NASDAQ: RDHL) is a specialty biopharmaceutical company dedicated to the development and commercialization of innovative therapies for gastrointestinal, infectious, and oncological diseases. With a focus on late clinical-stage development and patented drug formulations, the company leverages extensive expertise in clinical research, regulatory strategy, and commercial operations to address unmet medical needs.

Core Business and Market Position

RedHill Biopharma excels in advancing therapeutic candidates from concept to market. Its dual approach of improving existing drugs and pioneering new therapeutic candidates has established a robust pipeline. The company’s flagship products include Talicia, a novel treatment for Helicobacter pylori infections, and Aemcolo, targeted for travelers' diarrhea. Alongside these commercially marketed drugs, RedHill is actively advancing a number of clinical-stage programs such as opaganib, a first‐in‐class, orally administered sphingosine kinase-2 selective inhibitor, and several other candidates (RHB-107, RHB-102, RHB-104, RHB-204) aimed at addressing critical indications in oncology, viral infections, radiation protection, and inflammatory diseases.

Research and Development Excellence

Emphasizing rigorous research and robust clinical validation, RedHill’s R&D strategy leverages both internal expertise and strategic collaborations with U.S. government agencies and leading academic institutions. The company’s clinical trials and research programs are designed to meet the rigorous standards expected in the biopharmaceutical industry, enhancing its credibility and establishing its authority in the field. Through its focus on clinical efficacy, safety, and patented drug formulations, RedHill reinforces its commitment to innovative therapies and patient outcomes.

Operational Strengths and Competitive Differentiators

A key strength of RedHill is its experienced management team, which includes seasoned professionals from Israel, the U.S., Canada, and Europe. Their combined expertise in regulatory affairs, commercialization, and transactional experience allows the company to execute cost-efficient strategies while positioning its products favorably in a competitive market. This balanced approach not only strengthens its current market offering but also ensures continuous innovation and resilience in the face of industry challenges.

Investor and Market Relevance

For investors and market analysts, RedHill Biopharma represents a compelling blend of commercial successes and forward-looking clinical development programs. The company’s strategic focus on gastrointestinal and infectious therapies, combined with its robust pipeline and global network of expertise, underscores its value as a differentiated player in the specialty biopharmaceutical sector. Through its comprehensive approach to product development and commercialization, RedHill continues to solidify its position within a competitive and evolving market landscape.

News

RedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs

Rhea-AI Summary
RedHill Biopharma's opaganib selected by U.S. government for evaluation as a medical countermeasure against Sulfur Mustard exposure. Opaganib, a novel oral small molecule, shows promise for multiple indications including COVID-19 and oncology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.5%
Tags
none
-
News

RedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis - New Publication

Rhea-AI Summary
RedHill Biopharma Ltd. (RDHL) announces promising results of opaganib in treating radiation-induced lung inflammation and fibrosis. Opaganib, a selective SPHK2 inhibitor, significantly improved long-term survival in an in vivo mouse model post ionizing radiation exposure. The data suggest its potential as a medical countermeasure for radiation and cancer therapy. Opaganib is being evaluated for Acute Radiation Syndrome (ARS) and other indications like COVID-19, ARDS, filoviruses, and oncology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.36%
Tags
none
-
News

RedHill Biopharma Announces Closing of $8 Million Registered Direct Offering

Rhea-AI Summary
RedHill Biopharma Ltd. (NASDAQ: RDHL) has closed a registered direct offering for the purchase and sale of 10,000,000 of the Company's American Depositary Shares at a purchase price of $0.80 per ADS, with gross proceeds of $8 million. The Company also issued unregistered warrants to purchase up to 10,000,000 ADSs at an exercise price of $1.00 per ADS. The net proceeds will be used for general working capital, acquisitions, research and development, and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.62%
Tags
offering
News

RedHill Biopharma Announces $8 Million Registered Direct Offering

Rhea-AI Summary
RedHill Biopharma Ltd. (Nasdaq: RDHL) has entered into agreements for the purchase and sale of 10,000,000 of the Company's American Depositary Shares at a purchase price of $0.80 per ADS in a registered direct offering. Additionally, the Company will issue unregistered warrants to purchase up to 10,000,000 ADSs at an exercise price of $1.00 per ADS. The closing of the offering is expected to occur soon.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-39.81%
Tags
offering
-
News

RedHill Announces New USPTO Patent Grant for Talicia® for H. pylori Treatment Through 2042

Rhea-AI Summary
RedHill Biopharma Ltd. announces the issuance of a new patent by the USPTO covering Talicia as a method for eradicating H. pylori regardless of patient BMI, providing protection until May 2042. The patent is supported by previously published data showing Talicia's efficacy was unaffected by elevated BMI. Talicia has been granted market exclusivity for five years under the GAIN Act QIDP designation, in addition to three years' exclusivity granted for its approval under section 505(b)(2). Talicia is the leading branded first-line therapy prescribed by U.S. gastroenterologists for H. pylori eradication, a bacterial infection affecting approximately 35% of the U.S. adult population.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-39.81%
Tags
none
-
News

RedHill and U.S. Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against Ebola

Rhea-AI Summary
RedHill Biopharma Ltd. (Nasdaq: RDHL) announces positive in vitro results for investigational drugs opaganib and RHB-107 in combination with remdesivir, showing a distinct synergy in viral inhibition while maintaining cell viability. Opaganib and RHB-107 are expected to be effective against multiple viral targets, including COVID-19 and emerging viral variants.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.06%
Tags
none
News

RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

Rhea-AI Summary
RedHill Biopharma Ltd. (Nasdaq: RDHL) has announced that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5450(a)(1) for continued Nasdaq listing. The company maintained a minimum closing bid price of $1.00 or more for at least 10 consecutive trading days, achieving compliance on December 8, 2023. This comes after previously receiving notification that the bid price for the American Depositary Shares (ADSs) had closed below the minimum $1.00 per share requirement for continued listing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.49%
Tags
none
-
News

RedHill Announces New, Non-Dilutive External Funding of Entire RHB-107 COVID-19 300-Patient Phase 2 Study

Rhea-AI Summary
RedHill Biopharma Ltd. (RDHL) announces new non-dilutive external funding of approximately $4.8M to cover the RHB-107 arm of the ACESO PROTECT adaptive platform trial for early COVID-19 outpatient treatment. The Phase 2 RHB-107 arm has received FDA clearance to start and is estimated to be completed by the end of 2024. RHB-107 showed a 100% reduction in hospitalization due to COVID-19 in a U.S. Phase 2 study, with a 88% reduction in new severe COVID-19 symptoms and a faster recovery period. The study will compare investigational products to control in non-hospitalized adult SARS-CoV-2 infected participants with at least two moderate-severe symptoms at baseline.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.86%
Tags
clinical trial covid-19
-
News

RedHill Biopharma Announces FDA Grant of 5-Year U.S. Market Exclusivity for Talicia® with IP Protection Running to 2034

Rhea-AI Summary
RedHill Biopharma Ltd. (RDHL) has announced that the U.S. FDA has granted five years' market exclusivity for Talicia under the Generating Antibiotic Incentives Now (GAIN) Act Qualified Infectious Disease Product (QIDP) designation, in addition to three years' exclusivity granted for the approval of Talicia under section 505(b)(2). Talicia is protected by its broad intellectual property suite to 2034. Talicia is the leading branded first-line therapy prescribed by U.S. gastroenterologists for the eradication of H. pylori, a bacterial infection that affects approximately 35% of the U.S. adult population.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
216.46%
Tags
none
News

RedHill Biopharma Announces the Transfer of its Listing to The Nasdaq Capital Market

Rhea-AI Summary
RedHill Biopharma Ltd. (Nasdaq: RDHL) has received approval from Nasdaq to transfer the listing of the American Depositary Shares (ADSs) to the Nasdaq Capital Market. The transfer will take place on November 15, 2023, with trading unaffected and continuing under the same ticker symbol of 'RDHL.' The transfer follows a delisting notification due to non-compliance with the minimum Market Value of Publicly Held Shares (MVPHS) requirement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.03%
Tags
none

FAQ

What is the current stock price of Redhill Biopharm (RDHL)?

The current stock price of Redhill Biopharm (RDHL) is $2.45 as of April 2, 2025.

What is the market cap of Redhill Biopharm (RDHL)?

The market cap of Redhill Biopharm (RDHL) is approximately 3.3M.

What is the primary focus of RedHill Biopharma?

RedHill Biopharma focuses on developing and commercializing therapies for gastrointestinal diseases, infectious diseases, and oncology through both innovative clinical-stage programs and proven commercial products.

Which products does RedHill currently commercialize?

The company promotes products like Talicia for the treatment of Helicobacter pylori infections and Aemcolo for travelers' diarrhea, addressing key gastrointestinal disorders.

What are some of the key clinical programs in RedHill's pipeline?

Key clinical candidates include opaganib, a first-in-class sphingosine kinase-2 inhibitor, and additional candidates such as RHB-107, RHB-102, RHB-104, and RHB-204, targeting various indications from oncology to pandemic preparedness.

How does RedHill differentiate itself in the biopharmaceutical industry?

The company differentiates itself through its focus on late-stage drug development, a dual strategy of enhancing existing therapies and developing new candidates, and a management team with global experience and a strong track record in pharma.

Why is RedHill considered an expert in clinical-stage drug development?

RedHill’s extensive R&D collaborations, rigorous clinical trials, patented drug formulations, and a highly experienced international team bolster its authority and expertise in the field.

What makes RedHill Biopharma attractive to investors?

Investors are drawn to RedHill due to its balanced blend of proven commercial products and a diversified, advanced clinical pipeline, backed by a strong research foundation and global operational expertise.
Stock RDHL logo
Redhill Biopharm

Nasdaq:RDHL

RDHL Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

RDHL Stock Data

3.31M
1.28M
6.77%
2.62%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
Israel
Tel Aviv